Skip to main navigation
Skip to main content
Skip to page footer
Back
Lucid Genomics GmbH
Lucid Genomics utilizes advanced AI models to read complete DNA information from the human genome for accelerated drug development. The spin-off from the Max Planck Institute and Charité focuses on precisely analyzing complex and previously unreadable regions of the so-called dark genome. Its target audience consists of research-driven pharmaceutical companies and clinics aiming to better understand genetic diseases and develop personalized therapies.
